183 related articles for article (PubMed ID: 32164877)
1. Adjuvant
Li J; Xing J; Yang Y; Liu J; Wang W; Xia Y; Yan Z; Wang K; Wu D; Wu L; Wan X; Yang T; Gao C; Si A; Wang H; Wu M; Lau WY; Chen Z; Shen F
Lancet Gastroenterol Hepatol; 2020 Jun; 5(6):548-560. PubMed ID: 32164877
[TBL] [Abstract][Full Text] [Related]
2. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials.
Chen ZN; Mi L; Xu J; Song F; Zhang Q; Zhang Z; Xing JL; Bian HJ; Jiang JL; Wang XH; Shang P; Qian AR; Zhang SH; Li L; Li Y; Feng Q; Yu XL; Feng Y; Yang XM; Tian R; Wu ZB; Leng N; Mo TS; Kuang AR; Tan TZ; Li YC; Liang DR; Lu WS; Miao J; Xu GH; Zhang ZH; Nan KJ; Han J; Liu QG; Zhang HX; Zhu P
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):435-44. PubMed ID: 16690431
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma.
Zhang Z; Bian H; Feng Q; Mi L; Mo T; Kuang A; Tan T; Li Y; Lu W; Zhang Y; Zhang M; Tian R; Chen Z; Zhu P
Cancer Biol Ther; 2006 Mar; 5(3):318-22. PubMed ID: 16481737
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival.
Lau WY; Lai EC; Leung TW; Yu SC
Ann Surg; 2008 Jan; 247(1):43-8. PubMed ID: 18156922
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
[TBL] [Abstract][Full Text] [Related]
8. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
Garin E; Tselikas L; Guiu B; Chalaye J; Edeline J; de Baere T; Assenat E; Tacher V; Robert C; Terroir-Cassou-Mounat M; Mariano-Goulart D; Amaddeo G; Palard X; Hollebecque A; Kafrouni M; Regnault H; Boudjema K; Grimaldi S; Fourcade M; Kobeiter H; Vibert E; Le Sourd S; Piron L; Sommacale D; Laffont S; Campillo-Gimenez B; Rolland Y;
Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):17-29. PubMed ID: 33166497
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation.
Bian H; Zheng JS; Nan G; Li R; Chen C; Hu CX; Zhang Y; Sun B; Wang XL; Cui SC; Wu J; Xu J; Wei D; Zhang X; Liu H; Yang W; Ding Y; Li J; Chen ZN
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25210200
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Artery Injection of
Chen H; Nan G; Wei D; Zhai RY; Huang M; Yang WW; Xing BC; Zhu X; Xu HF; Wang XD; Zhang XY; Zhu BR; Liu P; Cao G; Gao S; Hao CY; Yang RJ; Guo JH; Zhang X; Gao K; Wang K; Wang JF; Li ZY; Zhu LZ; Ding R; Li J; Zhao L; Shao YJ; Liu HC; Xia JL; Wang L; Kong LM; Chen ZN; Bian H
J Nucl Med; 2022 Apr; 63(4):556-559. PubMed ID: 34475235
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial.
Chen K; Xia Y; Wang H; Xiao F; Xiang G; Shen F
PLoS One; 2013; 8(2):e57397. PubMed ID: 23468980
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety.
Wei W; Jian PE; Li SH; Guo ZX; Zhang YF; Ling YH; Lin XJ; Xu L; Shi M; Zheng L; Chen MS; Guo RP
Cancer Commun (Lond); 2018 Oct; 38(1):61. PubMed ID: 30305149
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.
Lau WY; Leung TW; Ho SK; Chan M; Machin D; Lau J; Chan AT; Yeo W; Mok TS; Yu SC; Leung NW; Johnson PJ
Lancet; 1999 Mar; 353(9155):797-801. PubMed ID: 10459961
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.
Chen LT; Chen MF; Li LA; Lee PH; Jeng LB; Lin DY; Wu CC; Mok KT; Chen CL; Lee WC; Chau GY; Chen YS; Lui WY; Hsiao CF; Whang-Peng J; Chen PJ;
Ann Surg; 2012 Jan; 255(1):8-17. PubMed ID: 22104564
[TBL] [Abstract][Full Text] [Related]
16. [Clinical value of iodine [131I] metuximab infusion combined with TACE for treatment of patients with post-intervention relapse of mid or advanced stage hepatocellular carcinoma].
Li Z; Zhou JX; Ren JZ; Zhang WJ; Han XW
Zhonghua Gan Zang Bing Za Zhi; 2013 Oct; 21(10):728-33. PubMed ID: 24331628
[TBL] [Abstract][Full Text] [Related]
17. Radionuclide therapy of hepatocellular carcinoma.
Keng GH; Sundram FX
Ann Acad Med Singap; 2003 Jul; 32(4):518-24. PubMed ID: 12968558
[TBL] [Abstract][Full Text] [Related]
18. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
[TBL] [Abstract][Full Text] [Related]
19. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
20. 131I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study.
Ma J; Wang JH
Asian Pac J Cancer Prev; 2015; 16(17):7441-7. PubMed ID: 26625741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
